1. Non-Chemotherapy Combinations in CLL

2. Program Overview

3. CLL Drug Development Timeline

4. mAbs Approved for CLL

5. BCR Signaling in CLL

6. RESONATE: Ibrutinib vs Ofatumumab in Patients With R/R CLL

7. Ibrutinib in Patients With R/R Del(17p) CLL

8. Ibrutinib Monotherapy in Treatment-Naive CLL: 5-Year Outcomes

9. Ibrutinib + Rituximab vs Ibrutinib Monotherapy in TN and R/R CLL

10. Idelalisib + Rituximab vs Placebo + Rituximab in R/R CLL

11. Idelalisib + Rituximab in Patients With R/R Del(17p) CLL

12. Venetoclax

13. Venetoclax Monotherapy in R/R Del(17p) CLL

14. Venetoclax + Rituximab in R/R CLL: MRD Negativity After Treatment Discontinuation

15. MURANO: Venetoclax + Rituximab vs BR in R/R CLL

16. VenR vs BR in Patients by Del(17p) and TP53 and IGHV Mutation Status

17. PB MRD Negativity With VenR vs BR by Del(17p) and TP535 and IGHV Mutation Status

18. Rationale for Novel Agents/Combinations in Development: Potential Benefits

19. Novel Agents in Development: Acalabrutinib and Ublituximab

20. BTK Inhibitor Acalabrutinib Monotherapy or in Combination With Obinutuzumab

21. GENUINE: Ublituximab + Ibrutinib in Patients With High Risk CLL

22. Rationale for Combining BTK Inhibitor and BCL2 Inhibitor

23. CLARITY: Venetoclax + Ibrutinib in R/R CLL

24. CAPTIVATE: Ibrutinib + Venetoclax in TN CLL

25. Combination Approaches of Novel Agents

26. Venetoclax + Obinutuzumab in TN CLL

27. CLL14: Venetoclax + Obinutuzumab in Patients With TN CLL and Coexisting Medical Conditions

28. Triple Therapy: Obinutuzumab + Ibrutinib + Venetoclax in TN CLL

29. New Targets in R/R CLL

30. Ongoing Clinical Trials in CLL: Doublet Therapy

31. Ongoing Clinical Trials in CLL: Triplet Therapy

32. Take-Home Messages

33. Abbreviations

34. Abbreviations (cont)

35. Abbreviations (cont)